Table 5.

Acne treatments (up to the week 52 cutoff date)

Medications for acne,a n (%)	Patients with acne TEAEs
	UPA 15 mg + TCS, n = 23b	UPA 30 mg + TCS, n = 44b
No initiation of medication for acne	3 (13.0)	7 (15.9)
Topical medications	19 (82.6)	34 (77.3)
Anti-infectives	18 (78.3)	33 (75.0)
Fixed combination of benzoyl peroxide and clindamycin	4 (17.4)	1 (2.3)
Clindamycin	5 (21.7)	19 (43.2)
Nadifloxacin	10 (43.5)	15 (34.1)
Ozenoxacin	5 (21.7)	3 (6.8)
Corticosteroids	0	1 (2.3)
Fixed combination of oxytetracycline and hydrocortisone	0	1 (2.3)
Imidazole and triazole derivatives	2 (8.7)	1 (2.3)
Ketoconazole	2 (8.7)	1 (2.3)
Other topical antibiotics	0	1 (2.3)
Gentamicin	0	1 (2.3)
Other emollients and protectives	1 (4.3)	0
Heparinoid	1 (4.3)	0
Benzoyl peroxide	1 (4.3)	5 (11.4)
Topical retinoids	4 (17.4)	5 (11.4)
Adapalene	3 (13.0)	2 (4.5)
Fixed combination of adapalene and benzyl peroxide	2 (8.7)	3 (6.8)
Topical zinc	0	1 (2.3)
Ophthalmic medications	0	1 (2.3)
Fluoroquinolones	0	1 (2.3)
Ofloxacin	0	1 (2.3)
Oral medications	5 (21.7)	9 (20.5)
Macrolides	3 (13.0)	3 (6.8)
Roxithromycin	3 (13.0)	3 (6.8)
Other cephalosporins and penems	0	2 (4.5)
Faropenem	0	2 (4.5)
Other plain vitamin preparations	0	1 (2.3)
Flavine adenine dinucleotide	0	1 (2.3)
Pyridoxal phosphate hydrate	0	1 (2.3)
Second-generation cephalosporins	1 (4.3)	0
Cefaclor	1 (4.3)	0
Tetracyclines	2 (8.7)	6 (13.6)
Doxycycline	0	3 (6.8)
Minocycline	2 (8.7)	4 (9.1)

TCS topical corticosteroids, TEAE treatment-emergent adverse event, UPA upadacitinib

^aPlease refer to Japanese package insert for the approved indications for each medication

^bIncludes patients who received placebo (UPA 15 mg, n = 42; UPA 30 mg, n = 45) during the double-blind period and switched to UPA during the blinded extension period